Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China's New Pharma Law Leaves Key Questions Unanswered

Executive Summary

Much anticipated legislation signals flexibility over online sales of pharma products and definition of counterfeits, but the law also falls short on key elements of pharmaceutical innovation and intellectual property rights protection, says one legal expert.

You may also be interested in...



10 For 2020: Regulatory Trends To Watch In China

2019 was the year that China approved the first new drug for Alzheimer's in nearly two decades and for the first US approval of an original cancer drug from China. While the simmering US trade war has been addressed by a phase one agreement to be signed, other uncertainties marked a year dominated by a large vaccine scandal and resulting bankruptcy, and increasing calls to include China in global clinical development plans.

Vaccine Maker Bankruptcy Shows Regulatory Perils Of Business In China

China's Changchun Changsheng Biotech has been officially declared bankrupt, ending long-running speculation. The major vaccine maker’s dramatic fall has several take-away lessons for health companies operating in China, where several new regulations are taking effect.

Regulatory Digital Savvy: Taking China NMPA's New App For A Test Drive

At just the time when pretty much everything is going digital in China, the nation’s pharma regulatory agency has launched a new mobile application to put itself at your finger tips. And it’s time to give it a test drive.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS140781

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel